

30 May 2016

BIOSINTESE RECEIVES APPROVAL OF ANVISA FOR THE REGISTRATION OF THE POLYETHYLENE INSERT ECIMA™

Biosintese received today the approval from ANVISA for the registration application of the ECI^{Ma}™ highly cross-linked vitamin E polyethylene liners. This announcement marks an important step for the hip portfolio of biosintese, allowing the company to add the latest generation of polyethylenes enriched with vitamin E to the already established advanced Trinity™ acetabular system. The final benefit of ECI^{Ma}™ is generated through active stabilization provided by the blend of vitamin E, which has been shown through studies the continuous protection against the oxidation of polyethylenes in the hip joint. The stabilizing effect of vitamin E free radicals provides a natural barrier to the potential long-term oxidation that can occur in vivo.

Mauro Nagem Montebello, CEO of biosintese, added: "More advanced Polyethylenes guarantee a better quality of life for patients and reduced costs for health operators in the long term, which is directly in line with the mission and values of biosintese. "